Palle Serup

Palle Serup is a Professor at the University of Copenhagen's Faculty of Health and Medical Sciences, leading the Serup Group within the Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW). As principal investigator of both EU and NIH sponsored projects, he collaborates with teams of European and American scientists to expand knowledge of pancreatic development and related fields.

Professor Serup's research focuses on the role of cell-to-cell signaling in pancreatic endocrine development and the function of key transcription factors in beta cell specification. His work spans developmental biology, stem cell research, and diabetes-related mechanisms, with particular emphasis on Notch signaling pathways and transcription factor networks that govern cell fate decisions during organogenesis. The research has significant implications for understanding diabetes pathogenesis and developing regenerative medicine approaches.

Analysis of Serup's recent publications (2020-2025) reveals consistent focus on developmental signaling pathways including Notch, Wnt, BMP, and TGF-β across multiple organ systems. His research demonstrates how these pathways interact to determine cell fate in pancreatic development, intestinal regionalization, and thymus formation. The work shows increasing sophistication in combining stem cell models with molecular techniques to dissect developmental mechanisms relevant to human disease.

Professor Serup serves as principal investigator for major international research projects funded by the European Union and National Institutes of Health. His collaborative approach connects European and American research teams, creating a robust network for advancing pancreatic development research. The work has received significant attention, with multiple publications picked up by news outlets and shared widely on social media platforms.

The Serup Group operates within reNEW (Novo Nordisk Foundation Center for Stem Cell Medicine), part of a global consortium including research institutions in Denmark, Australia, and the Netherlands. This positioning enables the group to contribute to translational research aimed at developing stem cell-based therapies for incurable diseases, particularly those related to pancreatic dysfunction and diabetes.